Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting

Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting

Abstract Background Desmopressin is an important treatment option in nonsevere hemophilia A because it has several benefits compared with factor (F) concentrates, including no inhibitor risk and much lower costs. Despite these advantages, data are limited on the real‐world use of desmopressin in the...

Full description

Bibliographic Details
Main Authors: Anne‐Fleur Zwagemaker, Fabienne R. Kloosterman, Michiel Coppens, Samantha C. Gouw, Sara Boyce, Catherine N. Bagot, Erik A. M. Beckers, Paul Brons, Giancarlo Castaman, Jeroen Eikenboom, Shannon Jackson, Marieke J. H. A. Kruip, Frank W. G. Leebeek, Karina Meijer, Laurens Nieuwenhuizen, Ingrid Pabinger, Karin Fijnvandraat, the DYNAMO Study Group
Format: Article
Language:English
Published: Elsevier 2022-08-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
hemophilia A
desmopressin
factor VIII
hemorrhage
treatment
Online Access:https://doi.org/10.1002/rth2.12777

Internet

https://doi.org/10.1002/rth2.12777

Similar Items